Recent advances in non-small cell lung cancer targeted therapy; an update review
Lung cancer continues to be the leading cause of cancer-related death worldwide. In the last
decade, significant advancements in the diagnosis and treatment of lung cancer, particularly …
decade, significant advancements in the diagnosis and treatment of lung cancer, particularly …
Melanoma management: from epidemiology to treatment and latest advances
Simple Summary Melanoma is a major public health issue that claims the lives of thousands
of people every year. Furthermore, the outlook for the coming years is not encouraging with …
of people every year. Furthermore, the outlook for the coming years is not encouraging with …
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Background Dabrafenib plus trametinib improves clinical outcomes in BRAF V600-mutant
metastatic melanoma without brain metastases; however, the activity of dabrafenib plus …
metastatic melanoma without brain metastases; however, the activity of dabrafenib plus …
Targeted therapy in melanoma and mechanisms of resistance
The common mutation BRAFV600 in primary melanomas activates the mitogen-activated
protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) pathway and the …
protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) pathway and the …
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
S Kakadia, N Yarlagadda, R Awad… - OncoTargets and …, 2018 - Taylor & Francis
Approximately 50% of melanomas harbor an activating BRAF mutation. Combined BRAF
and MEK inhibitors such as dabrafenib and trametinib, vemurafenib and cobimetinib, and …
and MEK inhibitors such as dabrafenib and trametinib, vemurafenib and cobimetinib, and …
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Background Effective treatments for patients with cholangiocarcinoma after progression on
gemcitabine-based chemotherapy are urgently needed. Mutations in the BRAF gene have …
gemcitabine-based chemotherapy are urgently needed. Mutations in the BRAF gene have …
Targeting the ERK signaling pathway in melanoma
P Savoia, P Fava, F Casoni, O Cremona - International journal of …, 2019 - mdpi.com
The discovery of the role of the RAS/RAF/MEK/ERK pathway in melanomagenesis and its
progression have opened a new era in the treatment of this tumor. Vemurafenib was the first …
progression have opened a new era in the treatment of this tumor. Vemurafenib was the first …
[HTML][HTML] A review of epidemiology and cancer biology of malignant melanoma
Malignant melanoma is a neoplasm originating in the melanocytes in the skin. Although
malignant melanoma is the third most common cutaneous cancer, it is recognized as the …
malignant melanoma is the third most common cutaneous cancer, it is recognized as the …
BRAF-mutated non-small cell lung cancer: current treatment status and future perspective
N Yan, S Guo, H Zhang, Z Zhang, S Shen, X Li - Frontiers in oncology, 2022 - frontiersin.org
V-Raf murine sarcoma viral oncogene homolog B (BRAF) kinase, which was encoded by
BRAF gene, plays critical roles in cell signaling, growth, and survival. Mutations in BRAF …
BRAF gene, plays critical roles in cell signaling, growth, and survival. Mutations in BRAF …
Systemic therapy of metastatic melanoma: on the road to cure
J Steininger, FF Gellrich, A Schulz, D Westphal… - Cancers, 2021 - mdpi.com
Simple Summary Malignant melanoma is more dangerous than most other skin cancers due
to its ability to spread early and aggressively. Until the development of new therapeutic …
to its ability to spread early and aggressively. Until the development of new therapeutic …